Regen BioPharma Inc (RGBP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD.

Revenue TTM

0 150K 300K 450K Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 192K Q1 '16: 192K Q2 '16: 192K Q3 '16: 192K Q4 '16: 100K Q1 '17: 100K Q2 '17: 100K Q3 '17: 210K Q4 '17: 110K Q1 '18: 110K Q2 '18: 110K Q3 '18: 100K Q4 '18: 100K Q1 '19: 127.4K Q2 '19: 154.8K Q3 '19: 82.3K Q4 '19: 110K Q1 '20: 110K Q2 '20: 110K Q3 '20: 110K Q4 '20: 110K Q1 '21: 110K Q2 '21: 110K Q3 '21: 111.8K Q4 '21: 116K Q1 '22: 120.3K Q2 '22: 123.8K Q3 '22: 125.9K Q4 '22: 125.5K Q1 '23: 125.5K Q2 '23: 126.2K Q3 '23: 126.6K Q4 '23: 236.6K Q1 '24: 264K Q2 '24: 291.4K Q3 '24: 318.8K Q4 '24: 236.6K Q1 '25: 236.6K Q2 '25: 236.6K Q3 '25: 236.6K Q4 '25: 236.6K Q1 '26: 236.6K Q2 '26: 236.6K Q3 '26: 236.6K Q1 '16 Q3 '17 Q1 '19 Q3 '20 Q1 '22 Q3 '23 Q1 '25 Q3 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-3M -1.5M 0 1.5M 3M 4.5M Q4 '14: -706.4K Q1 '15: -733.9K Q2 '15: -1.2M Q3 '15: -1.6M Q4 '15: -2M Q1 '16: -2.5M Q2 '16: -2.6M Q3 '16: -2.8M Q4 '16: -3M Q1 '17: -2.8M Q2 '17: -2.7M Q3 '17: -2.4M Q4 '17: -2.5M Q1 '18: -2.9M Q2 '18: -2.7M Q3 '18: -2.2M Q4 '18: -1.7M Q1 '19: -1M Q2 '19: -818.2K Q3 '19: -830.6K Q4 '19: -756.8K Q1 '20: -692.7K Q2 '20: -501.2K Q3 '20: -379.8K Q4 '20: -209.3K Q1 '21: -93.1K Q2 '21: -66.7K Q3 '21: -92.9K Q4 '21: -200.8K Q1 '22: -288.7K Q2 '22: -352.2K Q3 '22: -368.7K Q4 '22: -339.6K Q1 '23: -697K Q2 '23: -699.4K Q3 '23: -725.6K Q4 '23: -687K Q1 '24: -345.9K Q2 '24: -368.1K Q3 '24: -390.9K Q4 '24: -417.2K Q1 '25: -355.8K Q2 '25: -368.1K Q3 '25: -300.9K Q4 '25: -338.5K Q1 '26: -828.8K Q2 '26: -869.1K Q3 '26: -803.9K Q1 '16 Q3 '17 Q1 '19 Q3 '20 Q1 '22 Q3 '23 Q1 '25 Q3 '26

Net Income TTM

-75M -50M -25M 0 25M 50M 75M Q4 '13: -355K Q1 '14: -472.7K Q2 '14: -588.4K Q3 '14: -679.6K Q4 '14: -756.4K Q1 '15: -766K Q2 '15: -9.4M Q3 '15: -10.8M Q4 '15: -11.2M Q1 '16: -12.8M Q2 '16: -5.1M Q3 '16: -5.9M Q4 '16: -7.8M Q1 '17: -8.4M Q2 '17: -8.6M Q3 '17: -8.9M Q4 '17: -7.8M Q1 '18: -8.1M Q2 '18: -7.9M Q3 '18: -5.4M Q4 '18: -5M Q1 '19: -2M Q2 '19: -1.2M Q3 '19: -5.5M Q4 '19: -2.6M Q1 '20: 214.5K Q2 '20: -3.5M Q3 '20: 4.1M Q4 '20: 3.4M Q1 '21: 2M Q2 '21: 6.5M Q3 '21: -4.2M Q4 '21: -6.8M Q1 '22: -5.8M Q2 '22: -73.3M Q3 '22: 1.1M Q4 '22: 2.4M Q1 '23: 1.4M Q2 '23: 68.5M Q3 '23: 1.4M Q4 '23: 1.2M Q1 '24: -624.2K Q2 '24: -691.6K Q3 '24: -722.5K Q4 '24: -662.4K Q1 '25: -1M Q2 '25: -929.8K Q3 '25: -966.9K Q4 '25: -1.3M Q1 '26: -1.7M Q2 '26: -715.7K Q3 '26: -1.2M Q2 '14 Q1 '16 Q4 '17 Q3 '19 Q2 '21 Q1 '23 Q4 '24 Q3 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-2.4M -1.6M -800K 0 800K 1.6M 2.4M Q4 '15: -1.2M Q1 '16: -1.4M Q2 '16: -1.6M Q3 '16: -1.6M Q4 '16: -1.7M Q1 '17: -1.8M Q2 '17: -1.7M Q3 '17: -1.7M Q4 '17: -1.9M Q1 '18: -2M Q2 '18: -2.1M Q3 '18: -1.7M Q4 '18: -1.6M Q1 '19: -1.1M Q2 '19: -824.6K Q3 '19: -810.5K Q4 '19: -481.8K Q1 '20: -307.5K Q2 '20: -185.6K Q3 '20: -118.3K Q4 '20: 18.6K Q1 '21: -5.7K Q2 '21: 0 Q3 '21: -63.9K Q4 '21: -1.1M Q1 '22: -1.4M Q2 '22: -1.5M Q3 '22: -1.6M Q4 '22: -606.9K Q1 '23: -338.2K Q2 '23: -272.5K Q3 '23: -235.8K Q4 '23: -173.9K Q1 '24: -325.8K Q2 '24: -482.1K Q3 '24: -567.7K Q4 '24: -751.5K Q1 '25: -655.6K Q2 '25: -547.5K Q3 '25: -430.9K Q4 '25: -383.6K Q1 '26: -515.2K Q2 '26: -477.2K Q3 '26: -445.2K Q1 '16 Q3 '17 Q1 '19 Q3 '20 Q1 '22 Q3 '23 Q1 '25 Q3 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 2B 4B 6B Q2 '13: 10K Q3 '13: 24.2M Q1 '14: 51.8M Q2 '14: 51.9M Q3 '14: 51.9M Q1 '15: 52M Q2 '15: 72M Q3 '15: 110.6M Q1 '16: 118.2M Q2 '16: 124.9M Q3 '16: 128.8M Q1 '17: 143.6M Q2 '17: 141.8M Q3 '17: 138.1M Q1 '18: 143.1M Q2 '18: 145.3M Q3 '18: 153.5M Q1 '19: 211.9M Q2 '19: 295.7M Q3 '19: 85.9M Q1 '20: 836M Q2 '20: 1.6B Q3 '20: 1.6B Q1 '21: 1.8B Q2 '21: 2.5B Q3 '21: 3.6B Q1 '22: 4.5B Q2 '22: 3M Q3 '22: 3.2M Q1 '23: 3.4M Q2 '23: 1.7M Q3 '23: 3.4M Q1 '24: 3.6M Q2 '24: 4.1M Q3 '24: 4.2M Q1 '25: 4.1M Q2 '25: 21.6M Q3 '25: 23.8M Q1 '26: 99.6M Q2 '26: 184.9M Q3 '26: 615.6M Q3 '14 Q3 '16 Q3 '18 Q3 '20 Q3 '22 Q3 '24 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.27 -0.18 -0.09 0.00 0.09 0.18 0.27 Q4 '14: -0.01 Q1 '15: -0.01 Q2 '15: -0.13 Q3 '15: -0.14 Q4 '15: -0.13 Q1 '16: -0.14 Q2 '16: -0.02 Q3 '16: -0.03 Q4 '16: -0.06 Q1 '17: -0.06 Q2 '17: -0.06 Q3 '17: -0.06 Q4 '17: -0.12 Q1 '18: -0.12 Q2 '18: -0.12 Q3 '18: -0.10 Q4 '18: -0.03 Q1 '19: -0.01 Q2 '19: -0.00 Q3 '19: -0.06 Q4 '21: -0.00 Q1 '22: -0.00 Q4 '24: -0.16 Q1 '25: -0.25 Q2 '25: -0.22 Q3 '25: -0.20 Q1 '15 Q1 '16 Q1 '17 Q1 '18 Q1 '19 Q1 '22 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.